Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Multiple Oral Doses of H008 (Keverprazan) in Healthy Volunteers
NCT05050188Phase 1Completed
- Sponsor
- Carephar
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of keverprazan in erosive esophagitis (EE) (6 cohorts), sponsored by Carephar. Primary endpoints: Number and incidence of Adverse Events (AEs) at Day 16, Number and incidence of subjects with clinically significant changes of physical examinations at Day 16 and 3 more. Started Jun 2021; status: completed.
02
Drugs
keverprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT05050188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050188.